Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ECCO 15 - ESMO 34 /
Compounds to improve disease control in advanced breast cancer

20th - 24th Sep 2009

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.10.09
Views: 7883
Rating:

Dr Peyman Hadji - Head of the Department of Endocrinology, Osteoporosis and Reproductive Medicine at Philipps-University of Marburg, Germany

Expert interview with Dr. Peyman Hadji, M.D conducted by Prof Gordon McVie. Compounds to improve disease control in Advanced Breast Cancer
To view or download the slides click here

Context / Quiz

Compounds to improve disease control in Advanced Breast Cancer

Target audience:

This educational activity is intended for medical, surgical and radiation oncologists, as well as allied oncology professionals who treat breast cancer.

Statement of need:

One new family of medicines, the bisphosphonates, were developed to prevent or treat established bone metastases. A potential extra benefit may unexpectedly be emerging, namely synergy with endocrine treatments. The potential clinical benefits for patients needs to be explained.

Learning objective:

After watching the discussion participants should be able to:

  • Understand the raison d'être of use of bisphosphonates in management of bone metastases, and potential preventive potentials in patients without bony disease.
  • Understand the clinical benefits of adding bisphosphonate to endocrine therapy to increase their antitumour efficacy.
  • Be aware of emerging therapeutic strategies incorporated in new clinical trials to treat breast cancer which has already progressed.

 

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.

Supported by an unrestricted educational grant from Novartis

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation